iBio, Inc. (IBIO)
NASDAQ
Closed
Sep 3, 2026
Day's Range
1.2952 wk Range
0.7700Overview - IBIO - iBio, Inc.
Key Statistics
Valuation
Enterprise Value
-10.09M
P/E (Trailing)
‪0.59‬
P/E (Forward)
‪-2.45‬
PEG Ratio
‪-0.0067‬
Price / Sales (TTM)
‪675.62‬
Price / Book
‪0.60‬
EV / EBITDA
‪0.34‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-30,138.00%‬
Return on Assets
‪-30.80%‬
Return on Equity
‪-65.69%‬
Ownership
Shares Outstanding
34.54M
Float
39.10M
Short % of Shares Outstanding
‪10.17%‬
Held by Insiders
‪1.32%‬
Held by Institutions
‪55.43%‬
Price stats
50-Day Avg
‪1.49‬
200-Day Avg
‪1.84‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
8 analysts
Average price target
‪$ 5.53‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - IBIO - iBio, Inc.
Peers - IBIO - iBio, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- IBIONASDAQiBio, Inc.67.56MMarket Cap+40.44%52-week change0.59P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt64.24BMarket Cap+25.70%52-week change40.24P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.35.60BMarket Cap-70.99%52-week change45.79P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE26.05BMarket Cap-8.41%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S17.75BMarket Cap+23.94%52-week change20.58P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.14.97BMarket Cap+34.73%52-week change-20.27P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.51BMarket Cap+8.62%52-week change176.46P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - IBIO - iBio, Inc.
About
iBio Inc. is a preclinical-stage biotechnology company developing next-generation biopharmaceuticals by leveraging artificial intelligence and advanced computational biology. The company focuses on creating novel antibody-based therapies for cardiometabolic diseases, obesity, cancer, and other difficult-to-treat…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
